John G. Stathopoulos

Suggest Changes
Learn More
BACKGROUND The efficacy and toxicity of gemcitabine (GEM) and irinotecan (CPT-11) is evaluated in previously untreated patients with inoperable or metastatic pancreatic cancer. PATIENTS AND METHODS(More)